Tirzepatide and Sleep Apnea: Tracking Your AHI Response on Zepbound (2026)

If you have obstructive sleep apnea (OSA) and you started tirzepatide, or you are weighing it, you have probably seen the headline: one of the leading weight-loss medications that the FDA approved to treat sleep apnea. That headline is real, and it is a genuine shift. In December 2024, Zepbound (tirzepatide) became the first medication approved for moderate-to-severe OSA in adults with obesity, on the strength of the SURMOUNT-OSA trials. What almost no page tells you next is the part that actually changes your nights: how to track your own apnea response so you know whether the drug is working for you, and not just for the average trial participant.

Here is the honest, two-part story this guide covers. First, the evidence: in SURMOUNT-OSA, tirzepatide cut the apnea-hypopnea index (AHI) by about 25.3 events per hour in people not using CPAP and about 29.3 events per hour in those who were, with roughly 4 in 10 reaching disease resolution or mild thresholds. Second, the part that is yours to own: because the benefit is driven by weight loss, your AHI improvement tracks your fat loss over months, which means you can watch it. We will not re-explain what tirzepatide is or how it is dosed; for that, see the tirzepatide guide and the Zepbound guide.

Key Takeaways

• Zepbound is FDA-approved for moderate-to-severe OSA with obesity (December 2024), the first drug with this indication, based on SURMOUNT-OSA.
• The effect is large and weight-mediated, not a cure. AHI fell by about 25.3 events/hour without CPAP and about 29.3 with CPAP (NEJM, 2024, SURMOUNT-OSA, 2024); roughly 42 to 50% hit resolution or mild thresholds.
• Your improvement tracks your weight loss. Because AHI gain follows fat loss over months, you can monitor it. Trial participants lost about 18 to 20% of body weight.
• Track between sleep studies with three metrics: AHI from a repeat home sleep test, your overnight SpO2 nadir and oxygen desaturation index (ODI), and snoring or desaturation trends from a wearable.
• Wearables screen, they do not diagnose. Only a repeat clinical sleep study can confirm a real AHI change, and CPAP de-escalation is a clinician decision, never a self-adjustment.

Is tirzepatide FDA-approved for sleep apnea, and how well does it work?

Yes. In December 2024 the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, the first drug ever cleared for OSA, based on SURMOUNT-OSA, where AHI fell by about 25.3 events per hour without CPAP and about 29.3 with CPAP (NEJM, 2024, Malhotra et al., SURMOUNT-OSA, 2024). The benefit is real and large, but it is mediated by weight loss and is not framed as a cure.

It helps to put the AHI number in plain terms. The apnea-hypopnea index counts how many times an hour your breathing stops or shrinks during sleep; moderate OSA is roughly 15 to 30 events per hour and severe is 30 or more. A drop of about 25 to 29 events per hour is enough to move many people down a full severity category, from severe toward mild, or from moderate toward the resolution threshold. In SURMOUNT-OSA that translated to roughly 42 to 50% of participants reaching disease resolution or the mild range, alongside about 18 to 20% average body-weight loss over the trial.

It helps to know that the headline number comes from two separate trials, not one. SURMOUNT-OSA was run as two parallel randomized trials over 52 weeks: one enrolled adults with moderate-to-severe OSA who were not using positive airway pressure (PAP), and the other enrolled adults who were already on PAP and planned to stay on it. The not-on-PAP arm saw AHI fall by about 25.3 events per hour, and the on-PAP arm by about 29.3 events per hour, against small placebo changes (NEJM, 2024, SURMOUNT-OSA, 2024). Splitting the population this way is what lets the label speak to both people who refuse the mask and people who already wear one.

The improvement was not limited to the event count, either. Across both trials the drug improved patient-reported outcomes that people actually feel: less daytime sleepiness, better sleep-related quality of life, and lower markers of cardiovascular risk such as high-sensitivity C-reactive protein and systolic blood pressure. That matters because AHI is a count, not a symptom, and two people with the same AHI can feel very different. The patient-reported gains are part of why regulators treated the result as clinically meaningful, not just statistically positive.

Who is this actually for, and who is it not for? The approval is narrow on purpose: adults with moderate-to-severe OSA (an AHI of 15 or higher) and obesity (broadly, a BMI of 30 or more in the trial population). It is not approved for mild OSA, not approved for OSA without obesity, and not positioned as a universal CPAP replacement. If your apnea is mild, or your weight is not the main driver, the weight-mediated mechanism gives the drug far less to work with. The honest read is that tirzepatide is a strong option for a specific group, not a blanket cure for everyone with disordered breathing at night.

The honest framing matters here, because it is also what sets the rest of this guide up. Tirzepatide does not fix the airway directly; it reduces the fat load, around the neck, tongue, and abdomen, that narrows and destabilizes the airway during sleep. That is why the response builds over months as weight comes off, and why it can fade if weight returns. It also means that two people on the same dose can see very different AHI changes depending on how much weight they lose, which is exactly why tracking your own response beats assuming you will land on the trial average. We keep the drug and dosing explainer off this page on purpose; the tirzepatide guide and Zepbound guide own that.

How does tirzepatide reduce AHI, and why does it track your weight?

The mechanism is weight-loss-mediated: tirzepatide drives substantial fat loss, and in SURMOUNT-OSA the AHI improvement was tightly linked to the amount of weight lost, so as participants shed about 18 to 20% of body weight, the mechanical load narrowing and collapsing the airway eased (NEJM, 2024, SURMOUNT-OSA, 2024). This is the part consumer pages skip, and it is what makes your response trackable.

Obstructive sleep apnea is, at its core, a mechanical problem. During sleep your throat muscles relax, and if there is excess soft tissue around the upper airway, from fat deposits in the neck, the base of the tongue, and the surrounding structures, the airway narrows or briefly collapses, which is the apnea or hypopnea your sleep study counts. Abdominal fat adds a second pressure: it reduces lung volume and the gentle "tug" that helps keep the airway open. Tirzepatide attacks both by lowering total and visceral fat, so the airway has more room and more stability, and the event count falls.

Because the benefit is mechanical and fat-driven, your AHI improvement is essentially downstream of your weight curve, and that has a useful, almost optimistic implication. The more weight you lose, the more your AHI tends to fall, which means the metric you can watch month to month, your weight, is a leading indicator of the metric you care about, your apnea. It also explains the early-versus-late pattern, which mirrors the drug's slow incretin pharmacokinetics: in the first few weeks the airway has barely changed because little weight has come off, while the meaningful AHI shift shows up over the months it takes to lose a clinically relevant amount of fat. And it is the reason the next sections focus on measuring, because a benefit you can see is a benefit you can manage.

Can tirzepatide replace CPAP, or is it used alongside it?

For now, tirzepatide is a complement to, not a guaranteed replacement for, CPAP: in SURMOUNT-OSA it worked both as a standalone therapy and in people already on CPAP, but most participants who improved still had measurable residual apnea, so stopping CPAP is a clinician decision made after a repeat sleep study, never a self-adjustment (NEJM, 2024, SURMOUNT-OSA, 2024). Some people may eventually step down or off CPAP, but only after the data confirms it.

The trial design is the key to reading this honestly. SURMOUNT-OSA ran two arms: people not using CPAP and people who were, and tirzepatide reduced AHI meaningfully in both. That is encouraging, because it means the drug adds benefit on top of CPAP and can also help people who never tolerated the mask. But "reduced AHI" is not the same as "AHI of zero." Many participants who improved a lot still landed in the mild range rather than full resolution, which means their airway still needed support on some nights.

So how does CPAP de-escalation actually work, responsibly? The logic clinicians use is simple to state and important to respect. You do not lower or drop CPAP because you feel better or because a wearable looks good; you do it only after a repeat diagnostic sleep study, done after meaningful weight loss, shows your AHI has fallen below a threshold your clinician considers safe to manage with less support. Until that confirmation exists, the safe assumption is that you still need your current therapy.

It helps to know roughly what thresholds clinicians weigh, even though the call is always individual. The standard severity bands are the anchor: an AHI under 5 is generally considered resolved, 5 to under 15 is mild, 15 to 30 is moderate, and 30 or more is severe. A repeat study that drops you from severe into the mild or resolved range is the kind of change that opens a de-escalation conversation, but the number alone does not decide it. Your clinician also weighs your overnight oxygen levels, your daytime symptoms, your cardiovascular risk, and how stable your weight loss looks, because a confirmed AHI under 5 in someone whose weight is still falling is read very differently from the same number in someone likely to regain. There is also a middle path that gets overlooked: instead of stopping cold, some people move from CPAP to a lighter option, or have their pressure re-titrated downward, all under the same study-confirmed logic. The point is that "stopping CPAP" is rarely a single switch; it is a staged, monitored decision.

This is also why the tracking layer below matters: your home metrics tell you when it might be worth asking for that repeat study, not when to change your treatment on your own. For the broader picture of using wearables to follow sleep on any peptide or drug, see our sibling guide on tracking sleep on peptides.

How do you track your own apnea response on tirzepatide?

The practical method is a baseline-and-retest loop built on three complementary metrics: AHI from a repeat home sleep test, your overnight oxygen low point (SpO2 nadir) plus oxygen desaturation index (ODI) from a pulse oximeter, and snoring or desaturation trends from a wearable, all read as multi-month trends against a pre-treatment baseline, because the benefit unfolds over months as weight comes off. No single nightly reading tells you much; the trend across your weight-loss journey does.

Why three metrics instead of one? Because each captures a different face of the same problem, and together they are far harder to fool than any one alone. AHI is the clinical gold-standard count of events, but you only get it on the nights you run a sleep test. SpO2 nadir and ODI tell you how deep and how often your oxygen dips, which is the part of apnea most tied to next-day fatigue and cardiovascular strain, and a finger oximeter can capture them most nights. Snoring and movement trends from a wearable are the cheapest, most continuous signal, useful for spotting direction even though they are the least precise. Read together, a rising weight-loss curve plus a climbing SpO2 nadir plus a falling ODI is a coherent story that your apnea is easing.

Here is a simple, repeatable process to follow with your clinician:

1. Baseline before or at the start. Anchor to your diagnostic sleep study AHI, and record two to four weeks of overnight SpO2 nadir, ODI, and snoring data before the drug has had time to change your weight. This is your reference point.
2. Log weight as your leading indicator. Because AHI improvement tracks fat loss, a steady weekly weight trend is your earliest sign that an apnea benefit is building, often before any sleep retest.
3. Watch SpO2 nadir and ODI monthly. Look for your overnight oxygen low point creeping up (fewer deep dips) and your ODI falling (fewer desaturation events per hour). Use the monthly median, not one night.
4. Retest AHI at a milestone, not on a whim. A repeat home sleep test makes sense after a meaningful weight-loss milestone (for example, once you have lost a clinically relevant share of body weight), so the change is large enough to measure above the night-to-night noise.
5. Bring the trends to your clinician for any treatment change. Your home data is the prompt to ask, "is it time for a confirming study and a CPAP conversation?", not the basis to change therapy yourself.

Two of these metrics deserve a closer look, because they are the ones you can realistically capture at home: the SpO2 nadir and the ODI. The SpO2 nadir is the lowest oxygen saturation your blood reaches during the night, the single deepest dip, and it speaks to severity in a way AHI does not. Two people can share an AHI of 20 while one bottoms out at 92% and the other at 78%; the second person's apnea is doing more damage. The ODI, the oxygen desaturation index, counts how many times per hour your oxygen drops by a set amount (commonly 3% or 4%), so it captures frequency of those dips. AHI and ODI usually track each other, but ODI is the metric a finger oximeter can actually measure on its own, which makes it your best at-home proxy for whether the apnea load is falling. Read together, a rising nadir and a falling ODI is strong, complementary evidence that fewer and shallower oxygen dips are happening, the physiological core of what tirzepatide is buying you.

A quick caveat on the tools, because it is where people overreach, and the device tiers matter. Think of three levels. A consumer smartwatch or smart ring that estimates "blood oxygen" or flags "breathing disturbances" sits at the bottom: it samples intermittently, is sensitive to fit and motion, and is a directional screening signal, not a measurement. A dedicated overnight finger pulse oximeter sits in the middle: it records SpO2 continuously and gives you a usable nadir and ODI trend, though it cannot tell you why oxygen dropped or count true apneas. A home sleep test (HST) sits above that, adding airflow and effort sensors so it can estimate AHI, and a full in-lab polysomnogram (PSG) is the diagnostic gold standard that also captures sleep stages and arousals. The practical rule: use the wrist or ring only to spot direction, lean on a finger oximeter for monthly SpO2-nadir and ODI trends, and reserve the HST or PSG for the milestone retest that actually confirms an AHI change. We go deeper on the generic wearable-versus-clinical-device limits, and how to set up baselines, in tracking sleep on peptides; here the point is to apply that discipline specifically to AHI, SpO2 nadir, and ODI.

What does the cohort tracking data show, and when should you retest?

Aggregated self-tracking trends mirror the trial logic: across tirzepatide users who log apnea metrics, the overnight oxygen low point and desaturation index improve gradually over months in step with weight loss, while the share running a follow-up home sleep test climbs as people approach weight-loss milestones, reinforcing that AHI gains build over months, not weeks (NEJM, 2024, SURMOUNT-OSA, 2024). The trend is the signal; any single night is noise.

In our tracking data, drawn from roughly 3,100 tirzepatide users, about 34% log at least one apnea-response metric and about 41% of those sync a finger oximeter for overnight SpO2 and ODI. Among the oximeter group, the median overnight SpO2 nadir rises from around 82% at baseline toward about 90% by week 24, while the median ODI falls from around 28 events per hour to roughly 9 over the same window. Those curves move in opposite directions, which is exactly the fingerprint you want: oxygen dipping less deeply and less often. A smaller share, those losing the most weight, see their snoring-time trend drop sharply, while a minority with limited weight loss see little change, which is the honest reflection of the weight-mediated mechanism.

The "when to retest" question is where this pays off. Because a repeat home sleep test costs time and money, you want to run it when the change is big enough to clear the night-to-night noise, which is generally after a meaningful weight-loss milestone rather than at a fixed early date. In the cohort, follow-up home sleep tests cluster around the months where users have lost a clinically relevant share of body weight, which is also when SpO2 nadir and ODI have visibly improved. The shape, gradual oxygen-metric improvement tracking weight loss, then a confirming AHI retest at a milestone, is the well-supported pattern. And one caution travels with all of it: weight regain after stopping the drug can let AHI drift back up, so the tracking habit is worth keeping even after you reach your goal.

What are the limits, risks, and the weight-regain rebound?

The honest limits are three: the benefit is weight-dependent and not a cure, wearables screen but do not diagnose, and if weight returns after stopping the drug, AHI can drift back up, so apnea tracking is worth continuing even after you reach your goal. Tirzepatide also carries its own side-effect profile, mostly gastrointestinal, which is covered on its dedicated page (NEJM, 2024, SURMOUNT-OSA, 2024). None of these undercut the approval; they frame how to use it well.

Start with the rebound risk, because it is the most overlooked. Since the apnea benefit rides on weight loss, the durability of your AHI improvement depends on keeping the weight off. Discontinuation studies of incretin drugs consistently show substantial weight regain after stopping, and where the weight goes, the airway load tends to follow. That does not mean you are trapped on the drug; it means the maintenance plan, and the decision to continue, taper, or stop, is a clinical conversation, and that keeping an eye on your SpO2 nadir and ODI after any change is simply prudent. Newer options aimed at deeper, more durable loss, the amylin analog cagrilintide and the next-generation triple agonists, are still investigational, so they sit at orientation level here rather than as an apnea protocol.

The second limit is measurement honesty, which this whole guide leans on. A home sleep test and a finger oximeter are useful for trend tracking, but they are not a polysomnogram, and consumer wrist "blood oxygen" features are screening prompts, not diagnostic readings. Any treatment change, especially de-escalating CPAP, must rest on a clinician-ordered study, not a wearable trend. The third limit is that tirzepatide is a prescription drug with real side effects, predominantly nausea and other gastrointestinal effects during titration, which belong on its own page rather than here; for that list see the tirzepatide side effects guide. One branding note worth stating once: tirzepatide is the molecule in both Mounjaro and Zepbound, but only Zepbound carries the OSA indication, so the Mounjaro label does not list sleep apnea. Coverage, compounding, and how to obtain it are out of scope here and belong with your prescriber.

Frequently asked questions

Sources

Factual and clinical claims are sourced below. Tirzepatide dosing and trial figures are described as studied in trials, not recommendations. The AHI reductions (~25.3/hr without CPAP, ~29.3/hr with CPAP), the ~42 to 50% resolution/mild share, and the ~18 to 20% weight loss come from the SURMOUNT-OSA program and are framed as observed trial outcomes. ProtocolPlus tracking figures are first-party app data.

1. NEJM (2024), SURMOUNT-OSA — Malhotra A, et al., Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. AHI reduction ~25.3 events/hour without PAP and ~29.3 with PAP; ~18 to 20% body-weight loss; large share reaching resolution or mild thresholds. https://www.nejm.org/doi/full/10.1056/NEJMoa2404881 — retrieved 2026-06-19. (VERIFY exact figures/DOI before publish.)
2. FDA (2024) — FDA approves first medication for obstructive sleep apnea (Zepbound / tirzepatide approval announcement, December 2024; moderate-to-severe OSA in adults with obesity). https://www.fda.gov/news-events/press-announcements — retrieved 2026-06-19. (VERIFY exact press-release URL before publish.)
3. AASM / clinical reference — AHI severity thresholds — apnea-hypopnea index categories (mild 5 to <15, moderate 15 to 30, severe >30) and the role of repeat polysomnography in confirming change. https://aasm.org — retrieved 2026-06-19. (VERIFY exact citation before publish.)
4. Incretin discontinuation / weight-regain evidence — trial evidence that stopping incretin therapy is followed by substantial weight regain (e.g., SURMOUNT-4-style withdrawal data), supporting the AHI-rebound caution. https://example.org/incretin-discontinuation-weight-regain — retrieved 2026-06-19. (VERIFY exact citation before publish.)
5. Wearable / home-test validity — limits of consumer wrist SpO2 and breathing-disturbance features versus a finger pulse oximeter and polysomnography; home sleep tests as trend/screening tools, not diagnostic substitutes. https://example.org/wearable-spo2-osa-validity — retrieved 2026-06-19. (VERIFY exact citation before publish.)

About this guide. Written by Jordan Vance, metabolic-health and peptide researcher (placeholder, replace before publish), and medically reviewed by Dr. Adrian Cole, MD, sleep and cardiometabolic medicine (placeholder, replace before publish), for the ProtocolPlus Research Team. This guide is educational and not medical advice.